Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis

Part of paid clinical trials in Aurora, Colorado.

Sponsor
Yale University
Study ID
NCT04173169
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 40 Years
Healthy Volunteers
Not accepted

Interventions

  • Elagolix 200 MG — DRUG
    Elagolix tablet
  • Placebo or SOC IVF — OTHER
    Sugar pill manufactured to mimic Elagolix 200mg

Study Details

A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist.

Key Dates

Start date
Mar 15, 2022
Status verified
May 2025
Primary completion
May 2, 2025
Completion
May 2, 2025

Study Design

Enrollment
103 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Pre-IVF Treatment with 60 day course of oral GnRH antagonist
    For those who agree to be randomized, subjects will be randomized to elagolix 200mg BID. The medication will be taken orally and subjects will be counseled to take the medication at the same time each day. This arm will also include participants who do not want to be randomized while choose elagolix.
  • Other: Pre-IVF Treatment with 60 day course of Placebo or SOC IVF
    For those who agree to be randomized, subjects will be randomized to placebo, BID. The medication will be taken orally and subjects will be counseled to take the medication at the same time each day. This arm will also include participants who want to continue their ongoing or planned IVF and follow standard of care (SOC) (SOC IVF) if they do not want to delay the IVF procedure.

Primary Outcome Measure

Live birth rate [ Time Frame: Up to 15 months ]

Locations (5)

Related coverage on Hipa.ai

Find similar trials in Aurora, CO

By condition

Related Studies